Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.

Authors

S Barbarot
A Wollenberg
J I. Silverberg, George Washington University
M Deleuran
G Pellacani
J C. Armario-Hita
Z Chen
B Shumel
L Eckert
A Gadkari
Y Lu
A B. Rossi

Document Type

Journal Article

Publication Date

4-29-2020

Journal

The Journal of Dermatological Treatment

Inclusive Pages

1-34

DOI

10.1080/09546634.2020.1750550

Comments

Online ahead of print

APA Citation

Barbarot, S., Wollenberg, A., Silverberg, J. I., Deleuran, M., Pellacani, G., Armario-Hita, J. C., Chen, Z., Shumel, B., Eckert, L., Gadkari, A., Lu, Y., & Rossi, A. B. (2020). Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.. The Journal of Dermatological Treatment, (). http://dx.doi.org/10.1080/09546634.2020.1750550

Peer Reviewed

1